

RAISING THE BAR IN BREAST CANCER CARE: Answering Clinically Relevant Questions

Friday, 26 September 2014
18.00-20.00
Sevilla Auditorium



This activity is provided by prIME Oncology.

FACULTY

Martine Piccart, MD, PhD (Chair)
Institute Jules Bordet
Brussels, Belgium

Javier Cortés, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain

David Miles, MD, FRCP
Mount Vernon Cancer Centre
London, United Kingdom

Edith A. Perez, MD
Mayo Clinic
Jacksonville, Florida, United States

This educational activity is supported by
F. Hoffmann-La Roche Ltd.



AGENDA

Welcome and introduction
Martine Piccart, MD, PhD

18.00 How do you measure success? Recent progress in breast cancer
Martine Piccart, MD, PhD

18.10 Interactive clinical opinion poll
All faculty

#1: Selection of therapy for high volume, recurrent HER2-negative metastatic breast cancer (MBC)
Javier Cortés, MD, PhD

#2: Optimizing outcomes in metastatic triple-negative breast cancer (TNBC): The search for targets
David Miles, MD, FRCP

#3: Advanced high-grade estrogen receptor (ER)-positive breast cancer: A wolf in sheep's clothing?
Edith A. Perez, MD

#4: Role of combining anti-HER therapies in the neoadjuvant setting for HER2-positive early breast cancer
Javier Cortés, MD, PhD

#5: Optimal anti-HER2 approach in metastatic HER2-positive breast cancer
Edith A. Perez, MD

#6: Consideration of patient preference in selecting anti-HER2 therapy
David Miles, MD, FRCP

19.50 Clinical pearls
Martine Piccart, MD, PhD

20.00 Adjourn

